logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Exelixis: Further Stretching Its Cabozantinib’s Market

Exelixis (EXEL)   completed the submission of a supplemental New Drug Application (sNDA) to the FDA for Cabometyx® (cabozantinib) tablets for previously treated patients with advanced hepatocellular carcinoma (HCC). The sNDA submission is based on results from the CELESTIAL randomized...

Read More

March 16, 2018

0

Regeneron Discovers the Therapeutic Target for Non-Viral Chronic Liver Diseases. Alnylam is Assigned to Discover and Create the Targeted RNAi Therapeutic

Regeneron (REGN)   and   Alnylam (ALNY)  announced a collaborative agreement aimed at identifying RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis (NASH) and potentially other related diseases. The agreement is not the first between the two firms, but...

Read More

March 22, 2018

0

Gilead Collaboration with Sangamo

Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for Cancer Kite , a  Gilead (GILD)  company, and  Sangamo Therapeutics (SGMO)   announced a worldwide collaboration agreement for using Sangamo’s zinc finger nuclease (ZFN)...

Read More

February 22, 2018

0

The FDA Approves AstraZeneca Checkpoint Inhibitor Imfinzi® for a Lung Cancer. A Probable Partnership Agreement Between Arbutus and Roivant

The Food and Drug Administration (FDA) approved  AstraZeneca (AZN)   Checkpoint inhibitor drug  Imfinzi ®  (durvalumab)  for patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT)....

Read More

February 22, 2018

0

The Meaning of a 10-0 Vote in Favor of Novartis' CAR T-Cell Therapy Approval.

A BIG YES for Novartis CAR-T product has come from the  Food and Drug Administration (FDA) advisory committee. The committee recommended FDA approval for Novartis product CTL019 for pediatric acute lymphoblastic leukemia. The Vote : The panel voted 10-0 in favor...

Read More

July 13, 2017

0

Thanks to Aimmune, You Might Be Able to Eat Peanut Butter by Next Year

On March 4, 2018,   Aimmune Therapeutics (AIMT)   – a biopharmaceutical company developing treatments for potentially life-threatening food allergies confirmed the superior news that brings hope to children and adults who are susceptible to peanut allergic reactions. The results...

Read More

March 5, 2018

0

Trogarzo’s FDA Approval Made Possible Managing Multidrug Resistant HIV 1 Infection

Extremely important news has come from Montreal, Canada carrying the announcement by  Theratechnologies (TSX:TH)   and its partner TaiMed Biologics (TaiMed) that the FDA has granted approval of  Trogarzo™ (ibalizumab- uiyk) Injection . The approval is for Trogarzo to be...

Read More

March 8, 2018

0

Gilead's Well Chosen New Acquisition Is Not the Last, It Is Just the Beginning

Many in Wall Street have been anxious, sitting on fire while waiting to learn, which biotech company  Gilead Sciences (GILD)  would decide upon acquiring that would deepen and enhance its pipeline. In Today’s news, a firm called Nimbus Therapeutics, LLC...

Read More

April 4, 2016

0

Human Longevity Firm Aims at Bringing the Missing Full Picture of Human Health

Years ago, a friend who is a highly regarded Immunologist lectured us during one of our visits to his home city Milano in Italy about the important role well written press releases play in highlighting the prominence of unknown, yet,...

Read More

April 7, 2016

0

Theravance Biopharma Drug Vibativ Overcomes Serious Infections. See Also: Juno Therapeutics in China

Dealing With Bacterial Resistance To Antibiotics    In the  N E W S THERAVANCE BIOPHARMA At the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID),  Theravance Biopharma (TBPH)   demonstrated that its drug  Vibativ ®  (televancin) possesses a...

Read More

April 11, 2016

0

  • Previous
  • 1
  • 2
  • ...
  • 34
  • 35
  • 36
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy